Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene

被引:37
作者
Wu, MH
Chen, PX
Wu, KL
Liu, WQ
Strom, S
Das, S
Cook, EH
Rosner, GL
Dolan, ME
机构
[1] Univ Chicago, Sect Haematol & Oncol, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Human Genet, Chicago, IL USA
[3] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA
[4] Univ Chicago, Ctr Canc Res, Chicago, IL USA
[5] Univ Chicago, Committee Clin Pharmacol & Pharmacogenet, Chicago, IL USA
[6] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[7] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA
[8] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX USA
来源
PHARMACOGENETICS | 2004年 / 14卷 / 09期
关键词
CES2; carboxylesterase; 2; haplotype; linkage disequilibrium; single nucleotide polymorphism;
D O I
10.1097/00008571-200409000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Carboxylesterases are members of the serine esterase super family important in the metabolism of a wide variety of substrates, including xenobiotics and prodrugs. There are two known carboxylesterases expressed in human liver, small intestine and other tissues, carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2). The aim of this study was to identify polymorphisms in the CES2 gene and determine whether these polymorphisms affect expression levels of CES2 or rate of metabolism of irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin). Microsome samples prepared from liver tissues of 78 normal individuals were used to determine the rate of hydrolysis of irinotecan and procaine (an anaesthetic hydrolysed by CES2 but not CES1). The rate of hydrolysis of irinotecan is highly variable among individuals, ranging from 2.7-138 pmol/mg protein/h (mean +/- SD 26.0 +/- 22.9). Fifteen single nucleotide polymorphisms (SNPs) were identified, one is in an exon, 9 are in introns, three are in the 3'-untranslated region (UTR), and two are in the 5'-flanking region. Eight of the 15 SNP loci have rare allele frequencies greater than 5%, of which three were greater than 20%. Genotyping of samples from the SNP Consortium demonstrated different distributions among African-Americans, Asian-Americans and European-Americans. We also analysed the haplotype structure and estimated linkage disequilibrium (LID). A SNP located in the 5'-UTR (5'-UTR-363) was found in LID with loci in intron 1 (Intron1 + 947, Intron1 + 1361, Intron1 + 1643). Haplotypes with homozygous rare alleles on these loci exhibit lower mRNA levels as determined by real time polymerase chain reaction (P < 0.01) and the incorporation of rare alleles in haplotypes correlate with reduced mRNA (P = 0.03). The 5'-UTR-363 SNP is located in one of the three promoters of CES2. However, we did not observe significant differences in CES2 activities (irinotecan and procaine hydrolysis) among individuals with different haplotypes. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:595 / 605
页数:11
相关论文
共 46 条
[1]   Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures [J].
Agresti, A ;
Caffo, B .
AMERICAN STATISTICIAN, 2000, 54 (04) :280-288
[2]   Approximate is better than "exact" for interval estimation of binomial proportions [J].
Agresti, A ;
Coull, BA .
AMERICAN STATISTICIAN, 1998, 52 (02) :119-126
[3]   A comparison of selected mRNA and protein abundances in human liver [J].
Anderson, L ;
Seilhamer, J .
ELECTROPHORESIS, 1997, 18 (3-4) :533-537
[4]  
[Anonymous], 2000, ARLEQUIN SOFTWARE PO
[5]  
Antonarakis SE, 1998, HUM MUTAT, V11, P1
[6]   MORE POTENT TRANSCRIPTIONAL ACTIVATORS OR A TRANSDOMINANT INHIBITOR OF THE HNF1 HOMEOPROTEIN FAMILY ARE GENERATED BY ALTERNATIVE RNA PROCESSING [J].
BACH, I ;
YANIV, M .
EMBO JOURNAL, 1993, 12 (11) :4229-4242
[7]   PURIFICATION, CLONING, AND EXPRESSION OF A HUMAN ENZYME WITH ACYL-COENZYME-A - CHOLESTEROL ACYLTRANSFERASE ACTIVITY, WHICH IS IDENTICAL TO LIVER CARBOXYLESTERASE [J].
BECKER, A ;
BOTTCHER, A ;
LACKNER, KJ ;
FEHRINGER, P ;
NOTKA, F ;
ASLANIDIS, C ;
SCHMITZ, G .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (08) :1346-1355
[8]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[9]   Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer [J].
Canal, P ;
Gay, C ;
Dezeuze, A ;
Douillard, JY ;
Bugat, R ;
Brunet, R ;
Adenis, A ;
Herait, P ;
Lokiec, F ;
MathieuBoue, A .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2688-2695
[10]   Determination of drug interactions occurring with the metabolic pathways of irinotecan [J].
Charasson, V ;
Haaz, MC ;
Robert, J .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (06) :731-733